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Depleting arginine is a recognized strategy of pathogens to evade immune effector 28 
mechanisms. Depletion depends on microbial enzymes such as arginases which are 29 
considered as virulence factors. The effect is mostly interpreted as being a consequence of 30 
successful competition with host enzymes for the substrate. However, both arginases and 31 
arginine deiminases (ADI) have been associated with pathogen virulence. Both deplete 32 
arginine but their reaction products differ. An ADI has been implicated in the virulence of 33 
Giardia duodenalis, an intestinal parasite that infects humans and animals causing significant 34 
morbidity. Dendritic cells (DC) play a critical role in host defense, also in a murine G. 35 
duodenalis infection model. Functional properties of these innate immune cells depend on the 36 
milieu in which they are activated. Here, the dependency of the response of these cells on 37 
arginine was studied using Giardia ADI and LPS-stimulated human monocyte-derived DC. 38 
Arginine depletion by ADI significantly increased TNF-α and decreased IL-10 and IL-12p40 39 
secretion. It also reduced up-regulation of surface CD83 and CD86 molecules that are 40 
involved in cell-cell interactions. Arginine depletion also reduced phosphorylation of S6K in 41 
DC suggesting the involvement of the mTOR signaling pathway. The changes were due to 42 
arginine depletion and reaction product formation, in particular ammonium ions. Comparison 43 
of NH4+ and urea revealed distinct immunomodulatory activities for these products of 44 
deiminases and arginases, respectively. The data suggest that a better understanding of the 45 
role of arginine-depleting pathogen enzymes for immune evasion will have to take enzyme 46 




Many pathogens are thought to compete with the host for arginine as part of their virulence 49 
mechanisms. This is best known for pathogens expressing arginases that compete for arginine 50 
with host nitric oxide synthases and thereby are considered to prevent anti-microbial nitric 51 
oxide (NO) formation (1, 2). However, also other arginine-metabolizing enzymes have been 52 
implicated in microbial virulence, in particular arginine deiminases (ADI). The latter enzymes 53 
are thought to be relevant in streptococcal infections (3, 4) and infections with the non-54 
invasive, gastrointestinal protozoan parasite Giardia duodenalis (5, 6), a medically significant 55 
cause of diarrheal syndromes and malabsorption (7, 8). 56 
Arginine is not only necessary for generation of NO but it plays also other important roles 57 
during immune response. Lack of arginine was shown to inhibit T-cell function (9), and 58 
arginine levels affect signaling via the mammalian target of rapamycin (mTOR) pathway as 59 
reported for other cells (10, 11). The mTOR pathway, in turn, was shown to contribute to the 60 
regulation of co-stimulatory surface marker levels on dendritic cells (DC; (1, 12, 13)). These 61 
cells play a crucial role during induction of an adaptive immune response by secreting 62 
cytokines and by cell-contact dependent interactions with T- and other immune cells. 63 
Although DC are important for adaptive immunity against microbial infections, the effect of 64 
pathogen-mediated arginine-depletion on their function is not known.  65 
Arginine-dependent virulence mechanisms of pathogens rely on enzymes such as arginases or 66 
deiminases that deplete arginine but also generate reaction products at the same time. Of note, 67 
these products differ between these classes of enzymes that generate ornithine and urea or 68 
citrulline and NH4+, respectively. Commonly, changes of immune cell responses due to 69 
different arginine levels have been studied by comparing responses in the presence or absence 70 
of arginine. However, this does not reflect the situation when arginine is depleted by an 71 
enzymatic reaction as it can be the case during infections. Yet, the combined effect of arginine 72 
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depletion by an enzymatic reaction and the ensuing product formation on immune cells has 73 
largely been ignored.  74 
Referring to G. duodenalis as a relevant model, we studied here the immunomodulatory 75 
effects of arginine-depletion by exposing human monocyte-derived DC to recombinant 76 
G. duodenalis ADI during DC activation with LPS. The effect of this treatment on IL-10, 77 
IL-12p40, and TNF-α secretion as well as cell surface expression of CD83 and CD86 was 78 
monitored. We show that both, arginine-depletion and NH4+ formation by the active parasite 79 
enzyme are immunomodulatory on monocyte-derived dendritic cells (moDC) causing an 80 
increase in TNF-α, as opposed to a decrease in IL-10 and IL12p40 production and a reduction 81 
of surface located CD86 and CD83. In particular the latter effect correlated with an inhibition 82 
of the mTOR pathway since phosphorylation of the mTOR S6K target protein was decreased. 83 
We furthermore show that NH4+ but not urea exacerbated the inhibition of IL-10 production 84 
and surface marker up-regulation compared with arginine depletion alone, suggesting a 85 





Material and methods 89 
 90 
Cell culture 91 
 92 
DC were cultured in RPMI 1640 (Sigma, Germany) supplemented with 10% FCS (Biochrom, 93 
Germany) or arginine-free RPMI (PanBiotech, Germany) supplemented with 10% dialyzed 94 
FCS (Biochrom). Both media contained 10 mM Hepes (Biochrom), penicillin (100 U/mL) - 95 
streptomycin (100 µg/mL) (PAA, Germany) and 50 µM 2-mercaptoethanol (Roth, Germany). 96 
 97 
G. duodenalis trophozoites, strain WB-C6 (ATCC 50803), were propagated in TYI-S-33 98 
medium as previously described (14). Genomic DNA was isolated with the DNeasy Blood & 99 
Tissue kit (Qiagen, Germany). 100 
 101 
 102 
Generation of recombinant proteins 103 
 104 
The ADI-coding sequence (Gd-adi) was amplified from genomic DNA of G. duodenalis 105 
strain WB-C6 by PCR using Pfu polymerase (Fermentas, Germany) and specific primers (5’-106 
aatgactgacttctccaaggataaaga-‘3 and 5’- tccctcacttgatatcgacgcagatgtca-‘3). The resulting 1.8 kb 107 
fragment was cloned into the expression vector pASG-IBA35 (StarGate cloning, IBA GmbH, 108 
Germany) according to the manufacturer’s manual to produce a recombinant protein with an 109 
N-terminal His6-tag. After transformation into E. coli DH5αZ1 cells (15), the His6-tagged ADI 110 
(pASG-IBA35_ADI) was purified from cultures grown in LB medium supplemented with 111 
100 µg/mL ampicillin (Roth) and 50 µg/mL spectinomycin (Sigma) overnight at 37°C 112 
without induction by anhydrotetracycline. Cells were harvested by centrifugation (8200 x g, 113 
10 min, 4°C) and then washed in ice-cold PBS. The pellet was resuspended in 25 mM Hepes 114 
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(Fluka, Germany), 150 mM NaCl (Merck, Germany), 5 mM imidazole (Merck) plus EDTA-115 
free protease inhibitor cocktail (Roche, Germany), pH 7.5 (Buffer A) and disrupted using a 116 
high pressure homogenizer (EmulsiFlex, Avestin, Germany). After centrifugation (15000 x g, 117 
30 min, 4°C), the supernatant was passed through a 0.45 µm pore size filter (Sartorius, 118 
Germany) and loaded onto a HisTrapTMFF column (GE Healthcare, Germany) pre-119 
equilibrated with Buffer A on an ÄktaFPLC system (GE Healthcare). Finally, protein was 120 
eluted in 25 mM Hepes, 150 mM NaCl, and 200 mM imidazole, pH 7.5 (Buffer B). Finally, 121 
imidazole was removed by desalting using a PD-10 column (GE Healthcare) and residual LPS 122 
by an EndoTrap® kit (Hyglos, Germany). Recombinant protein in 1x PBS was finally 123 
concentrated using a Vivaspin concentrator (5 kDa PES membrane, Sartorius). To obtain a 124 
catalytically inactive arginine deiminase mutant (ADIC424A), cysteine424 was changed to 125 
alanine using the QuikChange® mutagenesis kit (Stratagene). Site-directed mutagenesis PCR 126 
was performed using the primers 5’-gtacggctctctgcacgccgcatctcaggttgtt-‘3 and 5’-127 
aacaacctgagatgcggcgtgcagagagccgtac-‘3 and, the vector pASG-IBA35_ADI as template. 128 
Recombinant ADIC424A was expressed and purified as described for the wild-type enzyme. 129 
Purity of both recombinant proteins was controlled by SDS-PAGE and verified using Western 130 
blot. Protein concentration was determined using a BCA protein assay kit (Thermo Scientific 131 
Fisher, Germany). Enzymatic activity of recombinant ADI was measured by colorimetric 132 










Production of polyclonal antibody  141 
 142 
An alpaca was immunized four times (day 0, 21, 35, 49; Preclinics, Potsdam, Germany) with 143 
300 µg of purified recombinant ADI resuspended in 100 µL PBS plus adjuvant (complete 144 
Freund’s adjuvant for the 1st injection and incomplete Freund’s adjuvant for subsequent 145 
booster injections). Pre-immune serum was collected prior to the first immunization. After the 146 
last booster injection, the antiserum was obtained. 147 
For Western blot analysis the alpaca antiserum was diluted 1:2500 and the secondary 148 
horseradish-peroxidase-conjugated goat anti-llama IgG antibody (Bethyl Laboratories, USA) 149 
1:20000, both in 5% non-fat dried milk (Roth), 1xPBS, 0.05% Tween20 (Roth). 150 
 151 
 152 
Generation of human moDC 153 
 154 
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats of healthy 155 
volunteers (German Red Cross, Berlin, Germany) by density gradient centrifugation (Ficoll-156 
PaqueTM Plus, GE Healthcare). Monocytes were separated by magnetic cell sorting using 157 
CD14 MicroBeads (Miltenyi Biotec, Germany). Typically, cells were thereby enriched to 158 
≥90% CD14+ as determined by flow cytometry. To generate moDC, 3.0x106 monocytes were 159 
seeded into 6-well tissue culture plates. DC growth medium additionally contained 1000U/mL 160 
human rGM-CSF (Bayer, USA) and 10 ng/mL human rIL-4 (R&D Systems, Germany). After 161 
6 days, immature DC were harvested and the cell population was characterized by analyzing 162 
an aliquot by flow cytometry. Staining of surface markers revealed low levels of CD14 and 163 





DC stimulation and analysis of cytokine production and cell surface markers  167 
 168 
5x105 immature DC/mL were seeded into a 12-well tissue culture plate and cultured at 37°C 169 
either in DC growth medium or in arginine-free DC growth medium supplemented or not with 170 
2 mM of arginine (Merck), or citrulline (Sigma), and/or ammonium chloride (Sigma), 171 
respectively. Cells were exposed to different concentrations of recombinant ADI or ADIC424A 172 
and 1 µg LPS/mL (Escherichia coli 026:B6 from Sigma) was added at the same time to 173 
trigger DC maturation. Cell-culture supernatants were collected after 24 h and were frozen at -174 
80°C until determination of TNF-α, IL-10, IL-12p70 (all from eBioscience, Germany), IL-23 175 
(U-CyTech, Netherlands), and IL-12p40 (Biolegend, Germany) by ELISA following 176 
manufacturers’ protocols. DC were stained with anti-human FITC-CD14 (Immunotools), 177 
PerCP-CD86 (Abcam), PE-HLA-DR (Immunotools), AlexaFluor488-CD83 (Biolegend), or 178 
Dyomics647-CD25 (Immunotools) conjugated mAb or the relevant isotype controls 179 
(Immunotools). Data were acquired on a LSR II flow cytometer (Becton Dickinson, 180 
Germany) and analyzed using FlowJo software (Tree Star, Inc.). Dead cells were excluded by 181 
gating according to FSC/SSC characteristics. 182 
 183 
Western blot analysis 184 
 185 
One million immature DC/mL were seeded into a 12-well tissue culture plate in arginine-free 186 
DC medium containing rGM-CSF and rIL-4, further supplemented or not with 2 mM of 187 
arginine, citrulline and/or ammonium chloride. After 30 min of resting, cells were treated with 188 
2 µM rapamycin (Sigma), recombinant ADI or ADIC424A and further cultured at 37°C for 189 
90 min. The immature cells were then exposed to 1 µg/mL LPS for 30 min. Cells were 190 
harvested, centrifuged at 300 x g at 4°C for 10 min, and supernatants were then collected for 191 
citrulline detection. Cell pellets were washed twice in ice-cold PBS before resuspension in 192 
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lysis buffer [10 mM Tris-HCl (Roth) pH 7.2, 150 mM NaCl (Merck), 1% Triton X-100 193 
(Merck), 1% sodium deoxycholate (Sigma), EDTA-free protease inhibitor cocktail (Roche)]. 194 
To remove cell debris, samples were centrifuged for 5 min at 14000 x g at 4°C. Protein 195 
concentration of the supernatant was determined by using BCA protein assay (Thermo 196 
Scientific Fisher, Germany) according to the manufacturers’ protocol. A total of 50 µg protein 197 
was separated by SDS-PAGE and transferred to nitrocellulose membranes (Biorad, 198 
Germany). Membranes were blocked for 1 h in 5% non-fat dried milk (Roth), 1xTBS, 0.1% 199 
Tween20 (Roth) and incubated over night at 4°C with primary antibodies (Cell signaling, 200 
Germany) against p70-S6K (#9202), phospho-p70-S6K (#9205), E4-BP1 (#9452), phospho-201 
E4-BP1 (#9455) and β-actin (#4967) diluted 1:1000 in 5% BSA (Roth), 1xTBS, 0.1% 202 
Tween20. Bound antibodies were detected with horseradish peroxidase-conjugated goat anti-203 
rabbit IgG (Jackson ImmunoResearch, USA) diluted 1:2000 in 5% BSA, 1xTBS, 0.1% 204 
Tween20 and visualized on X-ray films (GE Healthcare) using ECL Plus Western Blotting 205 
Detection System (GE Healthcare). Quantification of Western blot signals was performed 206 
with ImageJ 1.42q software (NIH, USA). 207 
 208 
 209 
Descriptive statistics 210 
 211 
Data are given as mean ± SD. Statistical significance was assessed by paired t-test (two-212 
tailed). All analyses were performed using GraphPad Prism 5 software (GraphPad Software, 213 





Defining experimental conditions for arginine-depletion by recombinant, enzymatically active 217 
G. duodenalis ADI during DC activation in vitro  218 
 219 
The average daily intake of arginine by humans has been estimated to be 5 g of arginine, 220 
corresponding to 28 mmol, (17). It has been reported that an infected person sheds up to 109 221 
G. duodenalis organisms per day (18). We first aimed to estimate the effect of ADI activity on 222 
the amount of arginine that may be available to G. duodenalis during an infection. Thus, we 223 
determined the ADI activity per million trophozoites to be equivalent to approx. 0.02 U by 224 
preparing lysates from different isolates and determining their ADI activity (data not shown). 225 
Therefore, at least 20 units of enzyme may be produced per day of infection. One unit 226 
corresponds to 1 µmol arginine metabolized per minute, hence >28 mmol could potentially be 227 
turned over in one day. Thus, the infection with Gd has the potential to substantially deplete 228 
arginine in the gastrointestinal tract.  229 
We cloned the adi gene present in strain WB-C6 and produced the respective recombinant 230 
enzyme as well as an enzymatically inactive mutant ADIC424A (19), in which Cys at residue 231 
424 was replaced by Ala, as hexahistidine-tagged proteins in E. coli. Analysis by SDS-PAGE 232 
and Western blot of the two affinity-purified proteins demonstrated that the recombinant 233 
proteins were highly pure and behaved similar to the endogenous ADI parasite protein of 234 
66 kDa (Fig. 1). That was also described by others, but unlike we could not confirm the 235 
previously described higher molecular weight of 85 kDa for native Gd ADI (20). The purified 236 
wild type protein had an ADI activity of 6.8 U/mg. 237 
To achieve arginine-depletion by recombinant ADI in a standard 24 h DC stimulation assay 238 
enabling to study the consequences of arginine-depletion on DC, we calculated that 4 µg of 239 
active recombinant ADI will convert all free arginine in 43 min (culture volumes of 1 ml 240 
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RPMI containing 1.15 mM arginine), 10-fold less enzyme will achieve this in approx. 7 h and 241 
100-fold less enzyme would need nearly 72 h assuming a constant activity over time. Thus, 242 
we choose these amounts of the active enzyme to study dose dependence in the following DC 243 
activation experiments and used the inactive mutant to control for possible effects unrelated to 244 
enzyme activity.  245 
 246 
Enzymatic arginine depletion by ADI modifies pro- and anti-inflammatory cytokine secretion 247 
of LPS-activated moDC  248 
 249 
In the intestine, DC project cellular extensions between epithelial cells (IEC) into the lumen 250 
of the gut to sample antigens (21, 22). Through these projections they are thought to recognize 251 
microbe-associated molecular patterns by pattern recognition receptors and become 252 
stimulated to mature and migrate to peripheral lymph nodes where they initiate antigen-253 
specific immunity (23, 24). Maturing DC up-regulate cell surface markers (e.g. MHC, CD83, 254 
CD86) and release cytokines (e.g. IL-12, IL-10, TNF-α) to enable communication with and 255 
activation of T- and other immune cells (25). To model such conditions and investigate 256 
potential immunomodulatory effects of arginine limitation on DC function, we used human 257 
moDC that can be readily prepared in the necessary quantities, stimulated them with LPS, and 258 
exposed the cells to ADI. Citrulline concentrations in the culture supernatants were 259 
determined at the end of the 24 h assay period and confirmed the calculated effects of the ADI 260 
dilutions (see above and Fig. 2A) on arginine turn-over. As expected, addition of ADIC424A 261 
did not result in citrulline formation at all tested concentrations (Fig. 2A and data not shown). 262 
Cytokine concentrations in these supernatants were then determined by ELISA (Fig. 2B). 263 
LPS-activation of cells stimulated roughly a 100-fold increase in IL-12p40, TNF-α and IL-10 264 
in arginine-replete medium compared to non-activated controls (data not shown). In contrast, 265 
LPS-stimulated moDC exposed to 4 µg/mL of ADI produced significantly less IL-10 and IL-266 
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12p40. These values were 45% (P < 0.001, n = 7) and 17% (P < 0.01, n = 6) lower compared 267 
to control cells exposed to mutant ADIC424A, respectively. In contrast, TNF-α secretion by 268 
ADI-treated and LPS-activated moDC was increased and values were on average 74% (P < 269 
0.01, n = 6) higher then values of LPS-stimulated, mutant enzyme exposed control cells. 270 
Both, the decreased IL-10 and IL-12p40 and the increased TNF-α production, depended on 271 
ADI activity, indicating that the kinetics of arginine-depletion did matter. These data show 272 
that arginine depletion by ADI modulates cytokine secretion of LPS-activated moDC and, 273 
importantly, that the effects differ depending on the cytokine analyzed. 274 
 275 
Enzymatic arginine depletion by ADI reduces upregulation of surface CD83 and CD86 levels 276 
of LPS-activated moDC 277 
 278 
To investigate the influence of arginine depletion by ADI on the phenotype of maturing DC, 279 
moDC were stimulated with LPS and treated with ADI or its mutant ADIC424A as described 280 
above and analyzed for selected surface marker proteins levels by flow cytometry. Activation 281 
of immature moDC with LPS induced up-regulation of CD83 and CD86 (data not shown) as 282 
expected. In contrast, LPS-stimulated moDC treated with arginine-depleting levels of ADI 283 
expressed significantly less CD83 and CD86 than control cells. Surface CD83 was on average 284 
22% (P < 0.05, n = 3) and that of CD86 15% (P < 0.01, n = 4) lower than on LPS-treated, 285 
mutant enzyme-exposed control cells. The effects were again ADI dose dependent (Fig. 3B). 286 
The reduced up-regulation of surface CD83 and CD86 unlikely reflects a general effect on 287 
surface protein levels since HLA-DR abundance on LPS-activated moDC was not affected by 288 





ADI immunomodulatory effects on LPS-activated moDC result from both arginine depletion 292 
and product formation 293 
 294 
We asked next whether the modulatory effects of ADI on moDC functional phenotype 295 
resulted from arginine depletion and/or the formation of ADI reaction products citrulline 296 
and/or NH4+. To investigate possible cause effect relationships, moDC were generated as 297 
before, harvested and then seeded into arginine-free culture medium that was only 298 
subsequently supplemented with arginine, citrulline, and/or ammonium chloride, respectively. 299 
Cells were then treated as before with 4 µg of ADI or ADIC424A and were activated with LPS. 300 
After 24 h of incubation, supernatants were collected and citrulline content and cytokine 301 
concentration were determined. Furthermore, moDC were harvested and cell surface markers 302 
were analyzed.  303 
IL-10 and TNF-α secretion of cells grown in arginine-replete media were modulated as 304 
described above, i.e. ADI-treated LPS-activated moDC produced less IL-10 and more TNF-α 305 
than control cells (Fig. 4). MoDC stimulated in the absence of arginine showed a small 306 
decrease in IL-10 production but levels remained significantly higher than those of cells 307 
treated with ADI in the presence of arginine where citrulline and NH4+ could be formed 308 
(Fig. 4). The addition of the ADI products, in particular of NH4+ in the form of NH4Cl, 309 
reduced IL-10 levels to those observed in the presence of arginine and ADI. Similarly, CD83 310 
and CD86 surface levels were also reduced, although this did not reach statistical significance 311 
for the latter marker (data not shown). In contrast, increase in TNF-α production was mainly 312 
driven by arginine depletion (Fig. 4) and not affected by NH4+. The increase due to arginine 313 
depletion was reduced by citrulline, indicating that citrulline could substitute for arginine in 314 
this respect (Fig. 4). Supplementing DC with NH4+ during stimulation in the presence of 315 
arginine but with no ADI present also reduced IL-10 but had no effect on TNF-α production 316 
(Fig. 5). 317 
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Thus, the immunomodulation of moDC by ADI resulted from a combination of distinct 318 
effects of arginine depletion and/or citrulline and NH4+ product formation.  319 
 320 
NH4+ and urea, the reaction products of ADI and arginases, differ in their effect on cytokine 321 
secretion and surface marker profile of LPS-stimulated moDC  322 
 323 
As mentioned before, many pathogens are thought to evade NO-mediated immune clearance 324 
through arginine depletion by arginases, which will result in the formation of ornithine and 325 
urea (2). Immunomodulatory effects may thus be different from conditions where deiminases 326 
are relevant. We were therefore interested in comparing the immunomodulatory effects of 327 
NH4+ and urea. LPS-stimulated cells were incubated in medium devoid of arginine but 328 
supplemented with ammonium chloride or urea for 24 h and then supernatants were collected 329 
for the detection of IL-10 and TNF-α by ELISA (Fig. 6A) and CD83 and CD86 proteins by 330 
flow cytometry (Fig. 6B). Notably, cells stimulated in medium supplemented with urea 331 
produced significantly more IL-10 and displayed significantly higher levels of CD83 and 332 
CD86 surface proteins than cells stimulated in the presence of NH4+. In contrast and 333 
corroborating our result that TNF-α production was not affected by NH4+ (Fig. 4), no 334 
differences were noted between cells treated with NH4+ or urea with respect to TNF-α release.  335 
 336 
Arginine turn-over by ADI results in decreased phosphorylation of the mTOR-signaling 337 
pathway target S6K in LPS-activated moDC 338 
 339 
Previous studies suggested an inhibitory effect of branched-chain amino acids on the 340 
mTOR/S6K-signaling pathway, resulting in impaired maturation of moDC and particularly 341 
affecting CD83 expression (26). mTOR is a serine/threonine kinase that is present in two 342 
distinct protein complexes, mTORC1 and mTORC2. Activation of mTORC1 leads to 343 
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phosphorylation of the protein S6 kinase (S6K) and the eukaryotic initiation factor 4E (eIF-344 
4E) binding protein 1 (4E-BP1) that both are involved in the regulation of protein translation 345 
(27). Arginine levels have been shown to affect mTOR signaling in T-cells (10, 11). Since 346 
ADI by arginine depletion had immunomodulatory effects on moDC, we hypothesized that 347 
this may also involve the mTOR pathway in moDC. MoDC were seeded in arginine-free 348 
medium, then supplemented or not with arginine. The cells were treated with recombinant 349 
ADI, catalytically inactive ADIC424A or, as a positive control, with the mTOR inhibitor 350 
rapamycin and were activated with LPS. Cells were incubated for 24 h before determining 351 
CD83 surface levels (Fig. 7A). In the presence of arginine CD83 levels were lower on cells 352 
treated with ADI than on cells exposed to the mutant enzyme, as shown before. MoDC 353 
stimulated in the absence of arginine or in the presence of arginine and rapamycin also 354 
showed reduced levels of CD83 protein (Fig. 7A).  355 
To investigate whether the reduced CD83 surface levels caused by ADI activity correlated 356 
with mTOR signaling, treated cells were harvested 30 min after LPS stimulation to assess 357 
mTOR-dependent phosphorylation events. Cells were lysed and equal amounts of total 358 
protein were separated by SDS-PAGE. The abundance of phosphorylated protein of the 359 
mTOR target S6K was then determined by Western blot analysis and results were quantified. 360 
Suppression of S6K phosphorylation in moDC correlated with reduced CD83 surface protein 361 
levels and this depended on arginine levels (Fig. 7B). Control cells treated with rapamycin 362 
showed the expected suppression of S6K phosphorylation. Phosphorylation of 4E-BP1, 363 
however, did not depend on arginine availability (data not shown).  364 
These data suggest that arginine levels, similar to what has been shown for branched-chained 365 
amino acids (26), affect mTOR activity in moDC but also indicate a difference between 366 





We show here that arginine depletion by G. duodenalis ADI modulates surface markers and 370 
cytokine response of in vitro activated human moDC. The immunomodulation depended on 371 
both, depletion of arginine and the ADI reaction products, in particular NH4+. By 372 
investigating the consequences of arginine depletion we found that the mTOR pathway is 373 
implicated in the molecular signaling and leads to the modulation of DC responses. These 374 
findings add further evidence to the hypothesis suggested by others (28) that ADI is a 375 
molecularly defined virulence and pathogenicity factor of G. duodenalis. Arginine-depleting 376 
enzymes of pathogens have been implicated in immune evasion mechanisms because of 377 
competing for the same substrate as host NO synthases. Little attention has been paid to date 378 
to effects beyond this inhibition of microbial effector function. Our data implicate that 379 
arginine-metabolizing enzymes of pathogens are more widely involved in immunomodulation 380 
and suggest distinct roles for the reaction products of different enzyme classes in this process.  381 
Currently, the relevance of our in vitro findings for the understanding of the pathogenesis of 382 
giardiasis must remain speculative and further studies are required. Nonetheless, we would 383 
like to discuss their potential implications: Firstly and as mentioned before, DC in the 384 
intestine project extensions between epithelial cells into the lumen of the gut to sample 385 
antigens (21, 22). Although only two studies with murine cells have been published to date 386 
that investigated the interaction of Giardia parasites with DC (29, 30), they provided evidence 387 
for the importance of DC in controlling Giardia infection (30). The ability to modulate DC 388 
function could thus provide a selective advantage to the parasite and our calculations suggest 389 
that arginine depletion may indeed occur in situ.  390 
Secondly, arginine-dependent response modulation would be consistent with observations on 391 
the pathophysiology of human giardiasis. Atrophy of villi has been detected microscopically 392 
in intestinal biopsies of chronically infected patients, and symptomatic disease has been 393 
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correlated with a dysfunction of the epithelial barrier (31) but the process leading to this is not 394 
understood. These sequelae can, however, also be observed when intestinal biopsies are 395 
treated with TNF-α (32). TNF-α may thus have pathogenic properties in this context. Studies 396 
in mice showed that peak level Giardia parasite loads were around 10-fold higher in animals 397 
devoid of TNF-α (33) hence it was proposed that it has a protective function in giardiasis. 398 
However, in the same study transepithelial resistance was reduced to the same extent despite a 399 
much lower parasite burden in TNF-α responsive mice. An explanation consistent with the 400 
results from human biopsies exposed to TNF-α (31) could be that reduced epithelial integrity 401 
during giardiasis is due to parasite factors and TNF-α, the latter exerting a dual (protective 402 
and pathogenic) role. 403 
Thirdly, children suffering from symptomatic giardiasis were shown to have increased 404 
mucosal levels of pro-inflammatory cytokines including TNF-α, which decreased after anti-405 
parasitic treatment and resolution of symptoms while local levels of IL-10 increased after 406 
treatment (34). This is in agreement with our in vitro findings and may indicate that parasite 407 
ADI mediated arginine depletion impaired IL-10 and enhanced TNF-α secretion by mucosal 408 
DC in situ in these children. The relative abundance of IL-10 and TNF-α is recognized as a 409 
critical parameter in intestinal diseases in mice (35) and in humans (36, 37). 410 
Fourthly, although G. duodenalis ADI is found intracellularly as part of the arginine 411 
dehydrolase (ADH) pathway and this pathway is thought to exploit arginine as an energy 412 
source to produce ATP in these amitochondrial organisms (38), the protein is also released by 413 
the parasite. Microarray analysis of the transcriptional response to host cell contact had 414 
revealed an up-regulation of ADI mRNA (28), and ADI as well as ornithine carbamoyl 415 
transferase (OCT, the next enzyme in the ADH pathway) were released by the parasite in 416 
contact with intestinal cells in vitro and in vivo ((39) and S.B. unpublished data). The facts 417 
that ADI and OCT were detected in these assays and are also immunodominant antigens 418 
during infection (40, 41) indicate that significant amounts of the enzymes are extracellular 419 
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and therefore free citrulline may even be further metabolized to ornithine. It is tempting to 420 
speculate that this may exacerbate TNF-α production because the negative feedback of 421 
citrulline on this parameter would be reduced. Thus, release of ADH compounds could have 422 
evolved in part due to selective pressure by the host’s immune response.  423 
To our knowledge this is the first report showing an immunomodulatory effect of arginine 424 
depletion and NH4+ formation on the response of DC other than on NO formation. Precedence 425 
for a clinically relevant role of amino acids in modulating immune responses exists (42, 43). 426 
For DC it has been shown that branched-chain amino acids affect maturation, and it has been 427 
proposed that this modulation is a consequence of inhibition of the mTOR pathway (26). Our 428 
results are consistent with this hypothesis but extend the concept to arginine. Of note, NH4+ 429 
has recently been reported to modulate mTOR activity in yeast cells (44). This suggests that 430 
reaction products formed by arginine-depleting enzymes could further affect mTOR signaling. 431 
However, additional signaling pathways are likely to be involved in mediating the distinct 432 
effects of arginine depletion alone and NH4+ formation. The latter has recently also been 433 
invoked in the T cell inhibition mediated by Salmonella L-asparaginase II (45). Further 434 
studies are required to understand this comprehensively.  435 
In summary, we describe immunomodulatory effects of arginine depletion on human DC. 436 
Using ADI from G. duodenalis we show that this immunomodulation depends on arginine 437 
depletion and the products formed by the enzyme. This reveals novel facets of DC response 438 
modulation by arginine-metabolizing enzymes and may have implications for the general 439 
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Figure Legends 580 
 581 
Figure 1. SDS-PAGE and Western blot analysis of purified recombinant G. duodenalis 582 
arginine deiminase 583 
A, Coomassie-stained SDS-PAGE loaded with affinity-purified recombinant catalytically 584 
inactive ADIC424A (lane 1), recombinant enzymatically active ADI (lane 2) and molecular 585 
mass standard (lane 3). B, Antigenic identification of 0.5 µg affinity-purified recombinant 586 
ADI (lane 4), 0.5 µg catalytically inactive ADIC424A (lane 5) and native ADI in 2.9 µg of 587 
G. duodenalis (strain WB-C6) lysate (lane 6) by Western blot analysis using a polyclonal 588 
alpaca antiserum raised against ADI. Pre-immune serum used as control did not react with 589 






Figure 2. Enzymatic arginine depletion by ADI modulates cytokine secretion of LPS-594 
activated human moDC 595 
Immature moDC (5 x 105 per sample) were exposed to the indicated amounts of recombinant 596 
ADI or, as control, corresponding levels of ADIC424A (only highest amount shown) and 597 
1 µg/mL LPS was added. Citrulline content was determined as a measure of the cumulated 598 
ADI activity and arginine depletion over the 24 h assay time (A). DC cytokine secretion into 599 
supernatants was assessed by ELISA and is expressed as percentage of the amount secreted 600 
by LPS stimulated cells not exposed to any ADI protein (B). Bars in (A) represent the mean ± 601 
SD from experiments with DC prepared from seven different donors. Symbols in (B) 602 
represent values from individual donors with means indicated by horizontal lines.  Differences 603 
between the amount of cytokines secreted by cells exposed to mutant (control) or active ADI 604 





Figure 3. Enzymatic arginine depletion by ADI reduces CD83 and CD86 surface 608 
markers induction by LPS activation on moDC 609 
Cells were treated as described in Fig. 1 and all cells, except the non-stimulated control cells, 610 
were treated with 1 µg/mL LPS. After incubation for 24 h at 37°C, moDC were harvested, 611 
stained with cell surface marker-specific antibodies and analyzed by flow cytometry. 612 
(A) Representative dot plots for CD14/CD83 (top panel) and CD25/CD86 (bottom panel) 613 
expression with the respective mean fluorescence intensity (MFI) values for CD86 and CD83 614 
are shown. (B) Relative MFI in % of control LPS-stimulated cells for CD83 (n=3) and CD86 615 
(n=4) with moDC from different donors are shown. Horizontal lines correspond to mean 616 
values and differences between the respective MFI on cells exposed to mutant (control) or 617 





Figure 4. Depletion of arginine and formation of ADI reaction products citrulline and 621 
ammonium ions modulate moDC response to LPS activation 622 
Immature moDC after harvest were seeded into arginine-free growth medium. The medium 623 
was then supplemented as indicated with arginine, citrulline and/or ammonium chloride 624 
(2mM each; brackets indicate addition of ADI to arginine-replete medium to reflect formed, 625 
not supplemented products). Cells were activated with LPS and treated with ADI (●) or 626 
mutant ADIC424A (○) for control. Values correspond to % of the respective parameter 627 
determined for cells stimulated with LPS only in arginine-replete medium. After 24 h, 628 
supernatants were collected and cytokine concentrations determined by ELISA. Horizontal 629 
lines correspond to mean values and differences between the respective parameter determined 630 
with cells exposed to mutant (control) or active ADI were analyzed by paired t test (two-631 












Figure 5. Addition of NH4+ in the presence of arginine reduces IL-10 secretion of moDC 642 
after LPS activation  643 
Immature moDC were prepared and stimulated as described (Fig. 4) and medium was 644 
supplemented with arginine or arginine and ammonium chlorid. After 24 h, supernatants were 645 
taken and cytokine concentrations determined by ELISA. Each dot represents an independent 646 
experiment with moDC prepared from an individual donor and values are expressed as % 647 
difference to cytokine amounts produced by arginine supplemented, LPS-stimulated cells. 648 
Significance was tested against the null hypothesis that there is no differences between cells 649 
stimulated in the presence of arginine or arginine plus ammonium ion using paired t test (two-650 











Figure 6. Immunomodulation of LPS-activated moDC under arginine starvation is 660 
different between NH4+ and urea.  661 
MoDC were prepared as described in Fig. 4 and stimulated in arginine-free medium 662 
supplemented with either 2 mM of ammonium chloride or urea. After 24 h, supernatants were 663 
collected and cytokine concentrations determined by ELISA (A). The moDC were harvested 664 
and surface marker proteins were analyzed by flow cytometry (B). Dots represent values from 665 
experiments with cells from six (A) or four (B) individual donors and are expressed as % of 666 
control values obtained with LPS-activated cells with no supplement (paired t test (two-667 











Figure 7. ADI-mediated arginine depletion decreases mTOR-signaling in LPS-677 
stimulated moDC 678 
106 immature moDC were seeded in arginine-free growth medium into each well of a 12-well 679 
tissue culture plate. Arginine-free medium (ΔArg) was supplemented or not with 2 mM 680 
arginine and cells were treated or not with 4 µg of ADI, 4 µg of ADIC424A, or 2 µM 681 
rapamycin. For activation 1 µg/mL LPS was added after 2 h to each sample. (A) MoDC CD83 682 
surface marker levels 24 h after stimulation compared to stimulated control cells are shown. 683 
Bars represent the mean ± SD of independent experiments with five different donors (paired 684 
t test (two-tailed), *p < 0.05 compared with the respective control). (B) In parallel, 30 min 685 
after LPS stimulation, cells were harvested, washed and lysed. 50 µg of cell extracts were 686 
separated by SDS-PAGE and p70-S6K, phospho-p70-S6K and β-actin were detected by 687 
immunoblotting and quantified by image analysis. Phosphorylated p70-S6K levels were 688 
normalized relative to β-actin and compared to stimulated control cells. Levels of total p70-689 
S6K levels were not significantly different between the different experimental groups. Bars 690 
represent the mean ± SD from five individual experiments with cells from different donors 691 
(paired t test (two-tailed), *p < 0.05, **p < 0.01 compared with the respective control).  692 
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